Table 2. Pulmonary function at the end of the 120-min reperfusion period.
Group | PA Pressure (mm Hg) | Compliance (cm H2O) | Oxygenation (mm Hg) |
---|---|---|---|
Control | 32.83 ± 0.48 | 4.93 ± 0.03 | 527.7 ± 1.1 |
A1 agonist | 24.17 ± 1.19 a, d | 5.70 ± 0.03 a, b | 551.7 ± 2.2 a, b |
A1 agonist + antagonist | 31.67 ± 0.56 b | 5.07 ± 0.03 b | 527.0 ± 2.1 |
A2A agonist | 18.50 ± 0.62 a, c, d | 5.87 ± 0.08 a, b | 569.2 ± 1.1 a, b, c, d |
A2A agonist + antagonist | 31.33 ± 0.84 b | 5.12 ± 0.48 b | 525.3 ± 2.9 b |
A3 agonist | 29.17 ± 1.66 b, c | 5.85 ± 0.04 a, b | 556.2 ± 4.0 a, b |
A3 agonist + antagonist | 32.00 ± 1.59 b | 5.07 ± 0.06 b | 530.0 ± 3.5 |
Adenosine | 21.67 ± 0.49 a | 5.33 ± 0.04 a | 538.3 ± 2.5 a |
p<0.0002 vs. Control,
p<0.02 vs. Adenosine,
p<0.01 vs. A1 agonist,
p<0.02 vs. A3 agonist